Title : Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes TrialArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the initiation of a Phase 3 cardiovascular outcomes trial for its investigational RNA interference (RNAi) therapeutic, plozasiran. This decision follows the promising outcomes demonstrated in multiple clinical trials, targeting diverse patient populations, including the pivotal Phase 3 PALISADE study for familial chylomicronemia syndrome (FCS) and the Phase 2 SHASTA-. Arrowhead’s Journey with Plozasiran Plozasiran is an RNAi therapeutic designed to silence specific messenger RNAs (mRNAs), thereby reducing the production of proteins implicated in various pathological conditions. With advancements in RNAi technology, Arrowhead has positioned plozasiran as a potent contender in treating cardiovascular and metabolic diseases.
Arrowhead Pharmaceuticals, Inc. (NASDAQ ARWR) has announced the initiation of a Phase 3 cardiovascular outc...
Published |
Modified
CSIMarket Newsroom | CSIMarket.com
CSIMarket Newsroom | CSIMarket.com
Sources for this article: Based on Arrowhead Pharmaceuticals Inc ’s official statement and Supply Chain Analysis by CSIMarket.com
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments